Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.
about
Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7Role of mGluR4 in acquisition of fear learning and memory.Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.Development of allosteric modulators of GPCRs for treatment of CNS disordersThe antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodentsInvolvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Leading compounds for the validation of animal models of psychopathology.A critical overview of animal models of psychiatric disorders: challenges and perspectives.Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons.β2-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate.Negative Allosteric Modulators of mGlu Receptor as Putative Antipsychotic DrugsDetermination of the absolute configuration of phosphinic analogues of glutamate
P2860
Q30402875-8FBDCBE7-CD93-460C-9292-A8D0B74CE023Q30528681-A2A7ED9F-82E0-4DD6-9C1E-E0D9D8A428E1Q33604654-87CF94E7-56E4-47F5-9E9E-E230667D9A00Q34125116-377FF60E-A76B-4570-A4EC-55BA6C48D5AFQ34373958-3D6107B6-3EFC-42AD-8FBE-E2DB2BC7DC55Q34798345-FBC3BF10-CDF3-4E23-9D02-D62F10CD3908Q37122707-BDE67F24-5001-4756-96B8-9C4DF60A7418Q37172877-8845FB18-52F6-441A-A961-35FD04CC9D03Q38056852-7D2C60F4-2764-47A2-81BF-DF1A098F9068Q38128733-6EACA7D2-BEF7-4322-9F35-93C764E078C6Q38165757-263DF4BB-A205-4716-A907-5BD7CEBE58A7Q38292149-76F32ABE-285E-4A69-BC8D-AF90C8E6E8F0Q39782221-724814EF-BB4F-4D3B-AC66-2373FF550C71Q40014174-A00B9CA8-8EDC-447B-9334-4F5703B92220Q41004843-AC386CDD-A3E2-48EC-BC25-A29F9BD38C71Q44487146-DEC791DD-AC18-484F-BF53-8A0F187DBC61Q48143733-A185589C-6C31-48A3-92B3-980EE902DB36Q50191924-F25C4D2C-BDF4-48C2-8C46-CC28AB11CA8CQ57191778-0858EF91-18BE-4556-9336-F9F3C432129AQ58878103-31491F28-D022-4E3B-92F3-3E27E20E157C
P2860
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@en
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@nl
type
label
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@en
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@nl
prefLabel
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@en
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@nl
P2860
P50
P1433
P1476
Opposing efficacy of group III ...... ive symptoms of schizophrenia.
@en
P2093
Francine Acher
Tomasz Lech
P2860
P2888
P304
P356
10.1007/S00213-011-2502-2
P577
2011-09-28T00:00:00Z
P5875
P6179
1016727085